CASI Pharmaceuticals (CASI) Competitors $5.10 -0.15 (-2.86%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CASI vs. JNCE, PSTI, VYGR, ITOS, CMPS, NGNE, CCCC, QTTB, PRQR, and ETONShould you be buying CASI Pharmaceuticals stock or one of its competitors? The main competitors of CASI Pharmaceuticals include Jounce Therapeutics (JNCE), Pluristem Therapeutics (PSTI), Voyager Therapeutics (VYGR), iTeos Therapeutics (ITOS), COMPASS Pathways (CMPS), Neurogene (NGNE), C4 Therapeutics (CCCC), Q32 Bio (QTTB), ProQR Therapeutics (PRQR), and Eton Pharmaceuticals (ETON). These companies are all part of the "medical" sector. CASI Pharmaceuticals vs. Jounce Therapeutics Pluristem Therapeutics Voyager Therapeutics iTeos Therapeutics COMPASS Pathways Neurogene C4 Therapeutics Q32 Bio ProQR Therapeutics Eton Pharmaceuticals Jounce Therapeutics (NASDAQ:JNCE) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment. Does the media prefer JNCE or CASI? In the previous week, CASI Pharmaceuticals had 4 more articles in the media than Jounce Therapeutics. MarketBeat recorded 4 mentions for CASI Pharmaceuticals and 0 mentions for Jounce Therapeutics. CASI Pharmaceuticals' average media sentiment score of 0.50 beat Jounce Therapeutics' score of 0.00 indicating that CASI Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Jounce Therapeutics Neutral CASI Pharmaceuticals Positive Is JNCE or CASI more profitable? Jounce Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -143.18%. Jounce Therapeutics' return on equity of -30.90% beat CASI Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Jounce TherapeuticsN/A -30.90% -26.31% CASI Pharmaceuticals -143.18%-181.52%-45.72% Do analysts prefer JNCE or CASI? CASI Pharmaceuticals has a consensus target price of $6.00, suggesting a potential upside of 17.65%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Jounce Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jounce Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CASI Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, JNCE or CASI? CASI Pharmaceuticals has lower revenue, but higher earnings than Jounce Therapeutics. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJounce Therapeutics$82M1.21-$50.92M-$2.56-0.73CASI Pharmaceuticals$33.88M2.33-$26.94M-$2.23-2.29 Do insiders & institutionals have more ownership in JNCE or CASI? 80.7% of Jounce Therapeutics shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 6.9% of Jounce Therapeutics shares are owned by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community believe in JNCE or CASI? Jounce Therapeutics received 82 more outperform votes than CASI Pharmaceuticals when rated by MarketBeat users. Likewise, 56.06% of users gave Jounce Therapeutics an outperform vote while only 50.25% of users gave CASI Pharmaceuticals an outperform vote. CompanyUnderperformOutperformJounce TherapeuticsOutperform Votes28256.06% Underperform Votes22143.94% CASI PharmaceuticalsOutperform Votes20050.25% Underperform Votes19849.75% Which has more volatility and risk, JNCE or CASI? Jounce Therapeutics has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. SummaryJounce Therapeutics and CASI Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Ad Darwin2025: Digital Asset Insights You Need to KnowCryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.Get your guide today! Get CASI Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CASI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CASI vs. The Competition Export to ExcelMetricCASI PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$78.85M$6.99B$5.38B$8.84BDividend YieldN/A8.15%5.13%4.09%P/E Ratio-2.2911.10105.1417.83Price / Sales2.33362.031,233.15158.41Price / CashN/A52.5940.4136.29Price / Book5.6710.377.096.50Net Income-$26.94M$153.60M$119.65M$226.22M7 Day Performance-4.32%4.60%2.25%4.03%1 Month Performance-7.10%-6.29%-2.33%4.92%1 Year Performance-8.93%33.41%33.98%29.30% CASI Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CASICASI Pharmaceuticals3.8222 of 5 stars$5.10-2.9%$6.00+17.6%-8.9%$78.85M$33.88M-2.29180JNCEJounce TherapeuticsN/A$1.88-2.6%N/A+0.0%$98.94M$82M-0.73137High Trading VolumePSTIPluristem TherapeuticsN/AN/AN/AN/A$32.35M$20,000.00-0.68153Analyst ForecastVYGRVoyager Therapeutics4.6684 of 5 stars$5.66+4.2%$17.00+200.6%-17.8%$308.91M$163.78M7.97100ITOSiTeos Therapeutics3.5107 of 5 stars$8.32+2.3%$31.50+278.6%-14.2%$303.96M$35M-2.6490CMPSCOMPASS Pathways2.9186 of 5 stars$4.41-0.9%$30.67+595.4%-27.1%$301.73MN/A-2.00120Positive NewsNGNENeurogene2.9117 of 5 stars$20.30+30.2%$60.83+199.7%N/A$301.46MN/A0.0090Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeCCCCC4 Therapeutics2.0493 of 5 stars$4.25+6.0%$10.00+135.3%+179.6%$300.01M$20.76M-2.50150News CoverageQTTBQ32 Bio1.6143 of 5 stars$24.55-9.2%$72.33+194.6%N/A$299.02M$1.16M-1.7239PRQRProQR Therapeutics2.0955 of 5 stars$3.62+0.3%$7.13+96.8%+151.4%$294.87M$17.88M-11.31180News CoverageETONEton Pharmaceuticals2.6904 of 5 stars$11.23+4.5%$13.00+15.8%+208.5%$290.14M$34.68M-51.0520High Trading Volume Related Companies and Tools Related Companies Jounce Therapeutics Competitors Pluristem Therapeutics Competitors Voyager Therapeutics Competitors iTeos Therapeutics Competitors COMPASS Pathways Competitors Neurogene Competitors C4 Therapeutics Competitors Q32 Bio Competitors ProQR Therapeutics Competitors Eton Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CASI) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CASI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CASI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CASI Stock Alerts